These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 36803930)

  • 1. New-onset MOGAD after first-dose SARS-CoV-2 mRNA vaccination with relapse following SARS-CoV-2 mRNA booster.
    Arismendez AA; Chopra J; Campbell T; Balsiger R; Vickers A
    Can J Ophthalmol; 2023 Aug; 58(4):e181-e183. PubMed ID: 36803930
    [No Abstract]   [Full Text] [Related]  

  • 2. Risk of disease relapse following COVID-19 vaccination in patients with AQP4-IgG-positive NMOSD and MOGAD.
    Dinoto A; Sechi E; Ferrari S; Gajofatto A; Orlandi R; Solla P; Maccabeo A; Maniscalco GT; Andreone V; Sartori A; Manganotti P; Rasia S; Capra R; Mancinelli CR; Mariotto S
    Mult Scler Relat Disord; 2022 Feb; 58():103424. PubMed ID: 35216793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
    Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
    Front Immunol; 2022; 13():863554. PubMed ID: 35711445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MOG encephalomyelitis after vaccination against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2): case report and comprehensive review of the literature.
    Jarius S; Bieber N; Haas J; Wildemann B
    J Neurol; 2022 Oct; 269(10):5198-5212. PubMed ID: 35737110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pronounced antibody elevation after SARS-CoV-2 BNT162b2 mRNA booster vaccination in nursing home residents.
    Chong Y; Goto T; Tani N; Yonekawa A; Ikematsu H; Shimono N; Tanaka Y; Akashi K
    Influenza Other Respir Viruses; 2022 Nov; 16(6):1066-1071. PubMed ID: 35962568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ancestral SARS-CoV-2 and Omicron BA.5-specific neutralizing antibody and T-cell responses after Omicron bivalent booster vaccination in previously infected and infection-naive individuals.
    Mak WA; Visser W; van der Vliet M; Markus HY; Koeleman JGM; Ong DSY
    J Med Virol; 2023 Aug; 95(8):e28989. PubMed ID: 37565645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial.
    Mallory RM; Formica N; Pfeiffer S; Wilkinson B; Marcheschi A; Albert G; McFall H; Robinson M; Plested JS; Zhu M; Cloney-Clark S; Zhou B; Chau G; Robertson A; Maciejewski S; Hammond HL; Baracco L; Logue J; Frieman MB; Smith G; Patel N; Glenn GM;
    Lancet Infect Dis; 2022 Nov; 22(11):1565-1576. PubMed ID: 35963274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relative effectiveness of booster vs. 2-dose mRNA Covid-19 vaccination in the Veterans Health Administration: Self-controlled risk interval analysis.
    Korves C; Izurieta HS; Smith J; Zwain GM; Powell EI; Balajee A; Ryder KM; Young-Xu Y
    Vaccine; 2022 Aug; 40(33):4742-4747. PubMed ID: 35773122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore.
    Ng OT; Marimuthu K; Lim N; Lim ZQ; Thevasagayam NM; Koh V; Chiew CJ; Ma S; Koh M; Low PY; Tan SB; Ho J; Maurer-Stroh S; Lee VJM; Leo YS; Tan KB; Cook AR; Tan CC
    JAMA Netw Open; 2022 Aug; 5(8):e2228900. PubMed ID: 36018588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of a bivalent mRNA vaccine booster dose to prevent severe COVID-19 outcomes: a retrospective cohort study.
    Arbel R; Peretz A; Sergienko R; Friger M; Beckenstein T; Duskin-Bitan H; Yaron S; Hammerman A; Bilenko N; Netzer D
    Lancet Infect Dis; 2023 Aug; 23(8):914-921. PubMed ID: 37062302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. mRNA-1273 boost after BNT162b2 vaccination generates comparable SARS-CoV-2-specific functional responses in naïve and COVID-19-recovered individuals.
    Lozano-Rodríguez R; Avendaño-Ortíz J; Terrón V; Montalbán-Hernández K; Casalvilla-Dueñas J; Bergón-Gutiérrez M; Mata-Martínez P; Martín-Quirós A; García-Garrido MÁ; Del Balzo-Castillo Á; Peinado M; Gómez L; Llorente-Fernández I; Martín-Miguel G; Herrero-Benito C; López-Morejón L; Vela-Olmo C; Cubillos-Zapata C; López-Collazo E; Del Fresno C
    Front Immunol; 2023; 14():1136029. PubMed ID: 37153580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and effectiveness of the booster dose of mRNA COVID-19 vaccines in people with multiple sclerosis: A monocentric experience.
    Bertozzi A; Mariottini A; Marchi L; Cristinzi MD; Nistri R; Damato V; Mechi C; Barilaro A; Massacesi L; Repice AM
    Mult Scler Relat Disord; 2023 Apr; 72():104582. PubMed ID: 36889098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Humoral COVID-19 vaccine response in patients with NMOSD/MOGAD during anti-IL-6 receptor therapy compared to other immunotherapies.
    Schwake C; Pakeerathan T; Kleiter I; Ringelstein M; Aktas O; Korporal-Kuhnke M; Wildemann B; Jarius S; Bayas A; Pul R; Ceylan U; Faissner S; Hellwig K; Ayroza Galvao Ribeiro Gomes AB; Lipps P; Pröbstel AK; Kümpfel T; Oswald E; Then Bergh F; Gödel C; Hümmert MW; Trebst C; Gold R; Ayzenberg I
    Mult Scler; 2023 May; 29(6):757-761. PubMed ID: 36748649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Booster vaccination protection against SARS-CoV-2 infections in young adults during an Omicron BA.1-predominant period: A retrospective cohort study.
    Wan J; Cazer CL; Clarkberg ME; Henderson SG; Lee SE; Meredith GR; Osman M; Shmoys DB; Frazier PI
    PLoS Med; 2023 Jan; 20(1):e1004153. PubMed ID: 36626376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protection against symptomatic infection with delta (B.1.617.2) and omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants after previous infection and vaccination in adolescents in England, August, 2021-March, 2022: a national, observational, test-negative, case-control study.
    Powell AA; Kirsebom F; Stowe J; Ramsay ME; Lopez-Bernal J; Andrews N; Ladhani SN
    Lancet Infect Dis; 2023 Apr; 23(4):435-444. PubMed ID: 36436536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity of bivalent omicron (BA.1) booster vaccination after different priming regimens in health-care workers in the Netherlands (SWITCH ON): results from the direct boost group of an open-label, multicentre, randomised controlled trial.
    Tan NH; Geers D; Sablerolles RSG; Rietdijk WJR; Goorhuis A; Postma DF; Visser LG; Bogers S; van Dijk LLA; Gommers L; van Leeuwen LPM; Boerma A; Nijhof SH; van Dort KA; Koopmans MPG; Dalm VASH; Lafeber M; Kootstra NA; Huckriede ALW; van Baarle D; Zaeck LM; GeurtsvanKessel CH; de Vries RD; van der Kuy PHM;
    Lancet Infect Dis; 2023 Aug; 23(8):901-913. PubMed ID: 37088096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COVID-19 infection after two doses of SARS-CoV-2 mRNA vaccine in multiple sclerosis, AQP4-antibody NMOSD and MOGAD.
    Yeo T; Quek AML; Yong KP; Tye JSN; Ratnagopal P; Soon DTL; Tan K
    Mult Scler Relat Disord; 2022 Sep; 65():104003. PubMed ID: 35803084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effectiveness of the first dose COVID-19 booster vs. full vaccination to prevent SARS-CoV-2 infection and severe COVID-19 clinical event: a meta-analysis and systematic review of longitudinal studies.
    Xu J; Lan X; Zhang L; Zhang X; Zhang J; Song M; Liu J
    Front Public Health; 2023; 11():1165611. PubMed ID: 37325336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An intranasal lentiviral booster reinforces the waning mRNA vaccine-induced SARS-CoV-2 immunity that it targets to lung mucosa.
    Vesin B; Lopez J; Noirat A; Authié P; Fert I; Le Chevalier F; Moncoq F; Nemirov K; Blanc C; Planchais C; Mouquet H; Guinet F; Hardy D; Vives FL; Gerke C; Anna F; Bourgine M; Majlessi L; Charneau P
    Mol Ther; 2022 Sep; 30(9):2984-2997. PubMed ID: 35484842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of bivalent mRNA booster vaccination against SARS-CoV-2 Omicron infection, the Netherlands, September to December 2022.
    Huiberts AJ; de Gier B; Hoeve CE; de Melker HE; Hahné SJ; den Hartog G; van de Wijgert JH; van den Hof S; Knol MJ
    Euro Surveill; 2023 Feb; 28(7):. PubMed ID: 36795500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.